Try our beta test site

A Single Dose Trial in Healthy Caucasians and Japanese Subjects Investigating the Pharmacokinetics of Somatropin

This study has been completed.
Information provided by:
Novo Nordisk A/S Identifier:
First received: June 30, 2009
Last updated: June 28, 2012
Last verified: June 2012
This trial was conducted in the United States of America (USA). The aim of this clinical trial was to investigate the pharmacokinetics of somatropin in healthy Japanese and Caucasian subjects, and to identify somatostatin-related adverse events.

Condition Intervention Phase
Growth Hormone Disorder
Adult Growth Hormone Deficiency
Drug: somatropin
Drug: placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Single-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group, Single Dose Trial in Healthy Caucasians and Japanese Subjects Investigating the Pharmacokinetics of Norditropin® (Norditropin® PenSet® 24)

Resource links provided by NLM:

Further study details as provided by Novo Nordisk A/S:

Primary Outcome Measures:
  • Area under the hGH concentration-time curve (GH AUC0-24h) [ Time Frame: from 0 to 24 hours following injection ]
  • Maximum hGH concentration (GH Cmax) [ Time Frame: from 0 to 24 hours following injection ]
  • Treatment Emergent Adverse Events [ Time Frame: from 0 to 24 hours following injection ]

Secondary Outcome Measures:
  • Time to maximum hGH concentration (GH tmax)
  • Area under the hGH concentration-time curve GH AUC0-∞)
  • Elimination half-life (GH t½)
  • Growth Factors (IGF-I and IGFBP-3)
  • Non-treatment Emergent Adverse Events

Enrollment: 86
Study Start Date: April 2000
Study Completion Date: June 2000
Primary Completion Date: June 2000 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   20 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Signed informed consent before any trial related activities
  • Japanese and Caucasian males respectively
  • Healthy subjects based upon medical history, physical examination, vital signs, ECG, serum biochemistry and haematology and urinalysis
  • Body Mass Index (BMI) between 17 and 30 m2/kg, inclusive
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00931476

United States, Hawaii
Novo Nordisk Clinical Trial Call Center
Honolulu, Hawaii, United States, 96814-4224
Sponsors and Collaborators
Novo Nordisk A/S
Study Director: Michael Højby Rasmussen, MD Novo Nordisk A/S
  More Information

Additional Information:
Responsible Party: Public Access to Clinical Trials, Novo Nordisk A/S Identifier: NCT00931476     History of Changes
Other Study ID Numbers: GHKIN-1253 
Study First Received: June 30, 2009
Last Updated: June 28, 2012

Additional relevant MeSH terms:
Dwarfism, Pituitary
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Bone Diseases, Endocrine
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases processed this record on February 20, 2017